Brown Advisory Inc. Sells 333,761 Shares of Kenvue Inc. (NYSE:KVUE)

Brown Advisory Inc. decreased its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 19.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,397,061 shares of the company's stock after selling 333,761 shares during the quarter. Brown Advisory Inc. owned about 0.07% of Kenvue worth $33,501,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its holdings in Kenvue by 3.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock valued at $5,249,665,000 after purchasing an additional 8,211,748 shares during the last quarter. Vanguard Group Inc. grew its holdings in Kenvue by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock valued at $4,665,908,000 after purchasing an additional 1,636,741 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Kenvue by 12.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock valued at $2,085,070,000 after purchasing an additional 10,682,003 shares during the last quarter. Geode Capital Management LLC grew its holdings in Kenvue by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company's stock valued at $980,989,000 after purchasing an additional 1,391,854 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in Kenvue by 61.5% in the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock valued at $912,059,000 after purchasing an additional 16,269,721 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Stock Performance

Shares of NYSE KVUE traded up $0.43 during midday trading on Friday, reaching $21.35. The company's stock had a trading volume of 25,967,559 shares, compared to its average volume of 16,055,380. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.86 and a quick ratio of 0.60. The stock has a market capitalization of $40.96 billion, a P/E ratio of 38.82, a PEG ratio of 3.25 and a beta of 0.83. The firm has a 50 day moving average price of $22.34 and a 200-day moving average price of $22.29. Kenvue Inc. has a 12-month low of $17.85 and a 12-month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. The business had revenue of $3.74 billion for the quarter, compared to analysts' expectations of $3.69 billion. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The business's revenue for the quarter was down 3.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.28 EPS. As a group, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were issued a dividend of $0.205 per share. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.84%. Kenvue's dividend payout ratio is currently 149.09%.

Analyst Ratings Changes

KVUE has been the topic of a number of research analyst reports. UBS Group raised their price target on Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Friday, May 9th. Redburn Atlantic initiated coverage on Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target for the company. Evercore ISI began coverage on Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price for the company. Citigroup reaffirmed a "neutral" rating on shares of Kenvue in a research note on Friday, June 13th. Finally, Barclays lifted their price objective on Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a report on Monday, May 12th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Kenvue has an average rating of "Hold" and an average price target of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.